These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6497565)

  • 41. Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness.
    Nerozzi D; Magnani A; Sforza V; Scaramucci E; Cerilli M; Moretti C; Frajese G; Antonozzi I; Meltzer HY
    Psychiatry Res; 1990 Nov; 34(2):139-47. PubMed ID: 2149613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postsynaptic supersensitivity in schizophrenia.
    Pandey GN; Garver DL; Tamminga C; Ericksen S; Ali SI; Davis JM
    Am J Psychiatry; 1977 May; 134(5):518-22. PubMed ID: 848578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Schneider's first-rank symptoms of schizophrenia: prevalence and diagnostic use. A study from Pakistan.
    Malik SB; Ahmed M; Bashir A; Choudhry TM
    Br J Psychiatry; 1990 Jan; 156():109-11. PubMed ID: 2297605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic valve of Schneider's first rank symptoms in schizophrenia.
    Chopra HD; Gunter M
    Br J Psychiatry; 1987 Jan; 150():132. PubMed ID: 3651667
    [No Abstract]   [Full Text] [Related]  

  • 46. Disintegration of the components of language as the path to a revision of Bleuler's and Schneider's concepts of schizophrenia. Linguistic disturbances compared with first-rank symptoms in acute psychosis.
    Ceccherini-Nelli A; Crow TJ
    Br J Psychiatry; 2003 Mar; 182():233-40. PubMed ID: 12611787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
    Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
    Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.
    Müller-Spahn F; Modell S; Ackenheil M; Brachner A; Kurtz G
    J Psychiatr Res; 1998; 32(5):265-71. PubMed ID: 9789204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroendocrine assessment of dopaminergic activity in schizophrenia.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Adv Biochem Psychopharmacol; 1977; 16():649-53. PubMed ID: 883563
    [No Abstract]   [Full Text] [Related]  

  • 51. Growth hormone response to clonidine in neuroleptic-free patients with multidagnostically defined schizophrenia.
    Keks NA; Copolov DL; McKenzie DP; Kulkarni J; Hassett A; Matheson B; Hill C; Mackie B; Singh B; Hirt J
    Psychiatry Res; 1993 Jul; 48(1):79-90. PubMed ID: 8416019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Schneider's first-rank symptoms.
    Carpenter WT; Strauss JS; Muleh S
    Arch Gen Psychiatry; 1973 Jun; 28(6):847-52. PubMed ID: 4707991
    [No Abstract]   [Full Text] [Related]  

  • 53. A study of Schneider's first-rank symptoms of schizophrenia in Nigerian patients.
    Gureje O; Bamgboye EA
    Br J Psychiatry; 1987 Jun; 150():867-9. PubMed ID: 3651746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prolactin responses to domperidone in chronic schizophrenia.
    Nerozzi D; Magnani A; Dastoli C; Ferri E; Capesciotti G; Antonozzi I; Frajese G; Meltzer HY
    Psychiatry Res; 1992 May; 42(2):159-69. PubMed ID: 1631251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequency of occurrence of Schneider's first rank symptoms in Schizophrenia.
    Marneros A
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):78-82. PubMed ID: 6489400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease.
    Durso R; Tamminga CA; Denaro A; Ruggeri S; Chase TN
    Neurology; 1983 Sep; 33(9):1229-32. PubMed ID: 6225034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Schneider's first rank symptoms: a review.
    Chandrasena R
    Psychiatr J Univ Ott; 1983 Jun; 8(2):86-95. PubMed ID: 6351144
    [No Abstract]   [Full Text] [Related]  

  • 58. Growth hormone response to apomorphine.
    Ferrier IN; Johnstone EC; Crow TJ
    Arch Gen Psychiatry; 1987 Jan; 44(1):93-4. PubMed ID: 3800586
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of naloxone or levallorphan on serum prolactin concentrations and apomorphine-induced growth hormone secretion.
    Lal S; Nair NP; Cervantes P; Pulman J; Guyda H
    Acta Psychiatr Scand; 1979 Feb; 59(2):173-9. PubMed ID: 420037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Schneider's first-rank symptoms.
    Fox HA
    Am J Psychiatry; 1987 Oct; 144(10):1377-8. PubMed ID: 3661785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.